NCT07730281RecruitingPhase 2
PRA-216 COPD Safety and Biomarker Study
A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 23 Jul 2026
- Start date
- 25 Aug 2026
- Primary completion date
- 1 Jun 2027
- Lead sponsor
- Prana Therapies Inc
- Diseases
- COPD
- NCT number
- NCT07730281
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 40
- From 25 Aug 2026 to the primary completion date, 1 Jun 2027
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Known history of illicit drug use or alcoholism within 12 months prior to the first dose of study agent
- Major surgery occurring within 8 weeks months prior to first dose of investigational product.
- Use of any marketed or investigational monoclonal or polyclonal antibody therapy within 4 months or 5 half-lives prior to visit 1.
Other illness
- Evidence of clinically significant pulmonary condition or disease other than COPD
- Any physical or psychological condition that prohibits study completion
- History of severe allergic reactions or hypersensitivity
Who the study is looking for
- Age 40-80
- Willing and able to attend all study visits, comply with study requirements.
- Able and willing to provide written informed consent
- Documented COPD diagnosis prior for at least 12 months prior to screening.
- Currently receiving maintenance COPD medications at a stable dose for at least 3 months prior to visit 1
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of the Sunshine Coast Coordinator of this site? Confirm its status | Birtinya | Australia | Recruiting |
| Emeritus Research Sydney Coordinator of this site? Confirm its status | Botany | Australia | Recruiting |
| Emeritus Research Camberwell Coordinator of this site? Confirm its status | Camberwell | Australia | Recruiting |
| Campbelltown Hospital Coordinator of this site? Confirm its status | Campbelltown | Australia | Not yet recruiting |
| Griffith University Coordinator of this site? Confirm its status | Southport | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.